ArriVent BioPharma, Inc. Common Stock

NASDAQ:AVBP

Biotechnology

Healthcare
$10.90 +1.40%

+$0.44 today

Market cap
$563.78M
Beta
1.42
P/E (TTM)
-9.8
EPS (TTM)
-$3.22
52W Low $16.10High $33.62

Volume 2.70M

Average 0.50M

AVBP Net Income

Bottom-line profit after all expenses, interest, and taxes.

ArriVent BioPharma, Inc. Common StockNASDAQ: AVBP

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$43.32M, compared with -$64.39M a year earlier. Trailing-twelve-month net income was -$145.24M.

Context

  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 7 analysts of -$145.74M (+12.4%) for the fiscal year ending Dec 2026, a step up from the -106.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$43.32M-21.9% QoQ
Last fiscal yearDec 2025
-$166.31M-106.6% YoY
LTMMar 2026
-$145.24M-14.0% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.7%-41.7%-74.5 pp
1 year-106.6%+12.4%+119.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(166.31M) USD
Year-over-year change
-106.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How AVBP compares with its peers on the latest reported figures

  • AVBP's LTM Mar 2026 net income of -$145.24M is the 8th highest of the 11 companies compared; the peer median is -$133.16M.
  • Its year-over-year change of -14.0% is the 7th highest of 11, against a peer median of +4.8%.
AVBP Competitors Peer median
Net Income for AVBP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EXELExelixis, Inc.LTM Jul 2026$860.62M +42.9%+62.5%35.3%
HCMHUTCHMED (China) LimitedLTM Jun 2025$466.88M +1212.4%—77.5%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$24.38M -35.9%+2396.3%10.7%
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026-$43.21M -948.8%——
TYRATyra Biosciences, Inc.LTM Mar 2026-$131.11M -36.0%——
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026-$135.21M -1.8%——
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-$140.06M +54.3%—62.2%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026-$145.24M -14.0%——
NUVBNuvation Bio Inc.LTM Jun 2026-$149.83M +26.2%—88.2%
ZLABZai Lab LimitedLTM Jun 2026-$188.21M +11.4%—41.9%
ERASErasca, Inc.LTM Sep 2026-$307.94M -141.2%——
Peer median (excluding AVBP) -$133.16M+4.8%+1229.4%52.0%

Competitors are the stored peer set for AVBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development6.43M30.43M64.88M79M153.35M
Selling, General & Admin2.26M6.47M9.71M15.3M24.18M
Operating Expenses8.7M36.91M74.59M94.31M177.53M
Depreciation & Amortization036.91M000
EBITDA(51.61M)0(69.33M)(80.49M)(166.31M)
EBITDA Margin—————
Operating Income(8.7M)(36.91M)(74.59M)(94.31M)(177.53M)
Operating Margin—————
Interest Income005.26M13.82M11.23M
Interest Expense00000
Other Income / Expenses(42.91M)05.26M13.82M11.23M
Income Before Tax(51.61M)(36.91M)(69.33M)(80.49M)(166.31M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(51.61M)(36.91M)(69.33M)(80.49M)(166.31M)
Net Margin—————
EPS (Basic)(40.44)(1.10)(2.17)(2.56)(4.32)
EPS (Diluted)(40.44)(1.10)(2.17)(2.56)(4.32)
Weighted Avg Shares1.28M33.49M31.96M31.47M38.46M
Weighted Avg Shares (Diluted)1.28M33.49M31.96M31.47M38.46M

ArriVent BioPharma, Inc. Common Stock

NASDAQ:AVBP

Intrinsic Alpha fair value

Locked

Current Price

$10.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.